Also trades as: NRSN (NASDAQ) · $vol 0M
NRSNW NASDAQ
NeuroSense Therapeutics Ltd.
1W: -55.6%
1M: +1.3%
3M: -72.4%
YTD: -86.7%
1Y: -93.7%
3Y: -88.2%
$0.04
-0.01 (-11.11%)
Weekly Expected Move ±85.5%
$-0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$10M
-21.3% ▼
Capital Expenditures
$3K
+89.7% ▲
5Y CAGR: -15.6%
Free Cash Flow
-$10M
-20.9% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$738K
+181.7% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$3M | -$4M | -$12M | -$10M | -$10M |
| Depreciation & Amort. | $3K | $3K | $89K | $21K | $22K |
| Stock-Based Comp. | $2M | $4M | $5M | $2M | $557K |
| Change in Working Capital | $71K | $273K | $750K | $2M | -$781K |
| Other Non-Cash Items | -$2K | $791K | -$1M | -$2M | $277K |
| Operating Cash Flow | -$695K | -$2M | -$8M | -$8M | -$10M |
| — Investing Activities — | |||||
| Capital Expenditures | -$9K | -$17K | -$70K | -$29K | -$3K |
| Acquisitions (Net) | $0 | $0 | $0 | $3K | $0 |
| Investment Purchases | $0 | $0 | -$4M | $0 | $0 |
| Investment Sales | $0 | $0 | $0 | $4M | $0 |
| Other Investing | $0 | $0 | $29K | -$6K | $4K |
| Investing Cash Flow | -$9K | -$17K | -$4M | $3M | $1K |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $1M | -$79K | -$80K | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | $800K | -$96K | $80K | -$391K |
| Financing Cash Flow | $508K | $12M | $4M | $4M | $11M |
| Net Change in Cash | -$196K | $10M | -$8M | -$903K | $738K |
| Cash End of Period | $699K | $11M | $4M | $3M | $3M |
| Free Cash Flow | -$704K | -$2M | -$8M | -$8M | -$10M |